TELA Bio, a commercial stage medical technology company focused on tissue reinforcement, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering.
The Malvern, PA-based company was founded in 2012 and booked $11 million in revenue for the 12 months ended June 30, 2019. It plans to list on the Nasdaq under the symbol TELA. TELA Bio filed confidentially on August 16, 2019. Jefferies and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
